Kyntra Bio (KYNB) Stock Price, News & Analysis

Company Overview

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $7.03 to $7.30
• 50-Day Range: $6.73 to $8.55
• 52-Week Range: $6.32 to $12.58
• Volume: 29,103 shs
• Average Volume: 23,879 shs
• Market Capitalization: $29.36 million
• P/E Ratio: 0.16
• Dividend Yield: N/A
• Price Target: $37.25
• Consensus Rating: Moderate Buy

Kyntra Bio Stock Analysis - MarketRank™

Kyntra Bio scored higher than 72% of companies evaluated by MarketBeat, and ranked 174th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kyntra Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Kyntra Bio has a consensus price target of $37.25, representing about 413.8% upside from its current price of $7.25.

Amount of Analyst Coverage

Kyntra Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kyntra Bio are expected to grow in the coming year, from ($16.04) to ($12.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyntra Bio is 0.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyntra Bio is 0.16, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.08.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.73% of the float of Kyntra Bio has been sold short.

Short Interest Ratio / Days to Cover

Kyntra Bio has a short interest ratio ("days to cover") of 4.63.

Change versus previous month

Short interest in Kyntra Bio has recently increased by 7.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kyntra Bio does not currently pay a dividend.

Dividend Growth

Kyntra Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.25

News Sentiment

Kyntra Bio has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Kyntra Bio this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for KYNB on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyntra Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.15% of the stock of Kyntra Bio is held by insiders.

Percentage Held by Institutions

72.71% of the stock of Kyntra Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KYNB
• CIK: 921299
• Web: www.kyntrabio.com
• Phone: (415) 978-1200
• Fax: 415-978-1902
• Employees: 570
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kyntra Bio: $37.25
• High Price Target: $43.00
• Low Price Target: $30.00
• Potential Upside/Downside: +413.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $45.30
• Trailing P/E Ratio: 0.16
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $183.45 million
• Net Margins: 2,199.13%
• Pretax Margin: -669.42%
• Return on Equity: N/A
• Return on Assets: -47.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.69
• Quick Ratio: 2.59

Sales & Book Value

• Annual Sales: $4.62 million
• Price / Sales: 6.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.20) per share
• Price / Book: -1.73

Miscellaneous

• Outstanding Shares: 4,049,000
• Free Float: 3,881,000
• Market Cap: $29.36 million
• Optionable: N/A
• Beta: 1.06